Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2RNA Levels
- 15 April 2006
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 80 (8) , 3732-42
Abstract
Transmission of human immunodeficiency virus type 1 (HIV-1) occurs primarily via the mucosal route, suggesting that HIV-1 vaccines may need to elicit mucosal immune responses. Here, we investigated the immunogenicity and relative efficacy of systemic immunization with two human ALVAC-HIV-1 recombinant vaccines expressing Gag, Pol, and gp120 (vCP250) or Gag, Pol, and gp160 (vCP1420) in a prime-boost protocol with their homologous vaccine native Env proteins. The relative efficacy was measured against a high-dose mucosal exposure to the pathogenic neutralization-resistant variant SHIVKU2(simian-human immunodeficiency virus). Systemic immunization with both vaccine regimens decreased viral load levels not only in blood but unexpectedly also in mucosal sites and protected macaques from peripheral CD4+T-cell loss. This protective effect was stronger when the gp120 antigen was included in the vaccine. Inclusion of recombinant Tat protein in the boosting phase along with the Env protein did not contribute further to the preservation of CD4+T cells. Thus, systemic immunization with ALVAC-HIV-1 vaccine candidates elicits anti-HIV-1 immune responses able to contain virus replication also at mucosal sites in macaques.Keywords
This publication has 56 references indexed in Scilit:
- Support for the RV144 HIV Vaccine TrialScience, 2004
- HIV Vaccine Trial JustifiedScience, 2004
- A Sound Rationale Needed for Phase III HIV-1 Vaccine TrialsScience, 2004
- Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)–Canarypox Vaccine in HIV‐Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine StudyThe Journal of Infectious Diseases, 2003
- Both Mucosal and Systemic Routes of Immunization with the Live, Attenuated NYVAC/Simian Immunodeficiency Virus SIVgpeRecombinant Vaccine Result in Gag-Specific CD8+T-Cell Responses in Mucosal Tissues of MacaquesJournal of Virology, 2002
- Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral TherapyJournal of Virology, 2002
- SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccineJournal of Medical Primatology, 2000
- Highly Attenuated HIV Type 2 Recombinant Poxviruses, but Not HIV-2 Recombinant Salmonella Vaccines, Induce Long-Lasting Protection in Rhesus MacaquesAIDS Research and Human Retroviruses, 1995
- HIV-1 expression in chimpanzees can be activated by CD8+ cell depletion or CMV infectionClinical Immunology and Immunopathology, 1992
- Characterization of the Secreted, Native gp120 and gp160 of the Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1990